LS513 Cells
CAD$759.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The LS513 cell line is a well-characterized colorectal carcinoma model derived from a primary tumor biopsy taken in 1985 from a 63-year-old Caucasian male patient. The tumor was classified as a Dukes' C mucin-secreting cecal carcinoma located at the Bauhin valve. LS513 cells are adherent in nature and have demonstrated multidrug resistance (MDR), making them a valuable model for studying drug resistance mechanisms in colorectal cancer. These cells exhibit a 30% colony-forming efficiency in methylcellulose and are tumorigenic in nude mice, further validating their use in oncogenic studies. At the genetic level, LS513 cells express several notable features. They are positive for the p53 wild-type oncogene and express carcinoembryonic antigen (CEA) on approximately 50% of the cells. Additionally, LS513 cells express major histocompatibility complex (MHC) class I antigens, including HLA and beta 2 microglobulin, but lack MHC class II antigens (HLA-DR, DQ, and DP). The cells also produce transforming growth factor beta 1 (TGF beta-1) at a rate of 83 pg per 106 cells per 24 hours. Notably, TGF beta-1 acts as an inhibitor of LS513 cell proliferation, whereas TGF beta-2 has no significant effect on their growth. Compared to the LS1034 cell line, LS513 cells are 100-fold less sensitive to TGF beta-1, indicating distinct responses to growth factor signaling between these two colorectal carcinoma models. LS513 cells exhibit a unique profile of antigen expression, with strong positivity for intercellular adhesion molecule 1 (ICAM-1) and HLA class I antigens. The lack of MHC class II antigen expression is particularly noteworthy, as it suggests potential immune evasion mechanisms that could be relevant to colorectal cancer progression and metastasis. These features, along with their resistance to multiple drugs and their ability to form tumors in immunocompromised mice, make LS513 cells a powerful tool for studying the molecular and cellular underpinnings of colorectal cancer, especially in the context of immune interactions and therapeutic resistance. |
|---|---|
| Organism | Human |
| Tissue | Colorectal |
| Disease | Adenocarcinoma |
| Synonyms | LS513, LS 513 |
Characteristics
| Age | 63 years |
|---|---|
| Gender | Male |
| Ethnicity | Caucasian |
| Morphology | Epithelial-like |
| Growth properties | Adherent |
Regulatory Data
| Citation | LS513 (Cytion catalog number 300457) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1386 |
Biomolecular Data
| Protein expression | CEA+ (50%), p53+ |
|---|---|
| Antigen expression | Carcinoembryonic antigen (CEA), ICAM-1, HLA class I positive |
| Tumorigenic | Yes, forms tumors in nude mice |
| Products | Transforming growth factor beta 1 (TGF beta-1, 83 pg per 10 exp6 cells per 24 hours) |
| Karyotype | Two stem lines can be distinguished. The main one was represented in 65% of the cells, with a modal number of 51,xY and 3 markers, M1 - der(1)t(1,15), M2 - der(2)t(2,3)der(3)t(2,3), M3, and a monosomy 15. The second stem line had a modal chromosome number of 52,xY and presented M2 and M3 plus an isochromosome for the long arm of chromosome 1 called M4. A trisomy 5,7, a tetrasomy 13, and a monosomy 2 and 3 were present in all of the cells analyzed, the line did not exhibit monosomy 15. |
Handling
| Culture Medium | DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Seeding density | 1 x 104 cells/cm2 |
| Fluid renewal | Every 3 days |
| Post-Thaw Recovery | After thawing, plate the cells at 5 x 104 cells/cm2 and allow the cells to recover from the freezing process and to adhere for at least 24 hours. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300457-201125 | Certificate of Analysis | 15. Jan. 2026 | 300457 |
| 300457-512 | Certificate of Analysis | 15. Jan. 2026 | 300457 |